ZIM
IONS icon

Zacks Investment Management’s Ionis Pharmaceuticals IONS Stock Holding History

Zacks Investment Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-61,540
Closed -$2.49M – 671
2016
Q1 		$2.49M Buy
61,540
+45,190
+276% +$1.84M 0.08% 175
2015
Q4 		$1.01M Sell
16,350
-6,396
-28% -$345K 0.03% 289
2015
Q3 		$919K Buy
22,746
+8,353
+58% +$432K 0.03% 313
2015
Q2 		$828K Buy
14,393
+1,436
+11% +$91.3K 0.03% 338
2015
Q1 		$825K Buy
12,957
+2,318
+22% +$157K 0.03% 328
2014
Q4 		$657K Sell
10,639
-1,873
-15% -$92.4K 0.02% 348
2014
Q3 		$486K Buy
12,512
+1,171
+10% +$41.5K 0.02% 415
2014
Q2 		$391K Sell
11,341
-6,038
-35% -$190K 0.01% 507
2014
Q1 		$751K Sell
17,379
-10,792
-38% -$523K 0.03% 310
2013
Q4 		$1.12M Buy
+28,171
New +$1M 0.04% 227

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Zacks Investment Management's IONS Position: Q2 2016 in Review

Zacks Investment Management sold out of Ionis Pharmaceuticals (IONS) in Q2 2016, closing a stake of 61,540 shares — an estimated $2.49M sold.

Zacks Investment Management first reported a position in IONS in Q4 2013 and held it in 10 quarters. The position peaked at $2.49M in Q1 2016. 282 funds tracked by Wall St. Rank hold IONS as of Q2 2016.

  • Zacks Investment Management reported no remaining Ionis Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Zacks Investment Management sold 61,540 Ionis Pharmaceuticals shares in Q2 2016, an estimated $2.49M.
  • Zacks Investment Management first reported a position in Ionis Pharmaceuticals in Q4 2013 and held it in 10 quarters.
  • Zacks Investment Management's Ionis Pharmaceuticals position peaked at $2.49M in Q1 2016.
  • 282 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2016.

Based on Zacks Investment Management's 13F filing for Q2 2016, filed 15 Aug 2016.